VIC-1911 + sotorasib

VIC-1911 + sotorasib is a **combination therapy** of two small molecules: VIC-1911, a selective oral inhibitor of aurora kinase A (AURKA), and sotorasib, an FDA-approved KRAS G12C inhibitor (marketed as Lumakras). VIC-1911 targets AURKA to impair centrosome maturation and cytokinesis, mechanisms critical for cancer cell division. Sotorasib binds covalently to KRAS G12C, a mutation driving tumorigenesis in certain cancers, locking it in an inactive state. Emerging evidence suggests the combination of AURKA inhibition (VIC-1911) with KRAS G12C inhibition (sotorasib) can **delay or overcome resistance** to KRAS G12C inhibitors observed in non-small cell lung cancer (NSCLC), as shown in preclinical and early clinical settings. This combination is currently under investigation in patients with advanced KRAS G12C-mutated NSCLC, including those with disease refractory to KRAS G12C inhibitors[1][3][5].

Brand names

Lumakras (sotorasib)

Other names

aurora kinase A inhibitor VIC-1911AMG 510 (sotorasib)